Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more) Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

XORTX Therapeutics Inc > FACTS OVER OPINIONS
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(64)
•••
Comment by SpaceLabson Nov 27, 2021 11:31pm
185 Views
Post# 34173042

RE:RE:RE:RE:FACTS OVER OPINIONS

RE:RE:RE:RE:FACTS OVER OPINIONSRedeNeck Answer is below:

1. 1.I have never seen any junior listing  from CSE on NASDAQ where IPO is DONE by an IDIOT Dr. Allen using a NO NAME BRANDED Fund Managers discounted by 30% and ONLY 13 Million shares after Rollback.

I hope the BOILER ROOMIES understand this  and stop BS about SHAKING IT. nothing left by Allen to SHAKE, he SHOOK it and CHOPPED the BRANCHES off, tell AB42 and RoadRunners to GRAB and SHAKE the TREE TRUNK you BUMS.!



yrunvs wrote: Hey Space Cadet,
Tell us what you really think about Dr.Allen, I am not sure if you have been clear enough the other 50 times. You are a broken record with a skip in it. SELL YOUR STOCK AND MOVE ON PLEASE, and take your other alias posters with you.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities